Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 26Multiple Myeloma 20Recurrence 19Leukemia, Myeloid, Acute 19Neoplasm Metastasis 17Colorectal Neoplasms 16Lymphoma, Non-Hodgkin 15Melanoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia 13Carcinoma, Renal Cell 13Ovarian Neoplasms 12Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 10Lung Neoplasms 10Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Carcinoma, Hepatocellular 9Adenocarcinoma 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8

Interventions

pembrolizumab 1brigatinib 1Paclitaxel 1Crizotinib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × Carcinoma, Squamous Cell × Clear all
NCT04472429 2025-11-03

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Incyte Corporation

Phase 3 Completed
308 enrolled 17 charts 1 FDA
Gastrointestinal

Anus Neoplasms, Carcinoma, Squamous Cell

NCT03284424 2024-08-23

MK-3475-629

Merck Sharp & Dohme LLC

Phase 2 Completed
159 enrolled 16 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT02737501 2021-08-20

ALTA-1L

Takeda

Phase 3 Completed
275 enrolled 23 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡